Kiniksa Pharmaceuticals (KNSA) News Today $20.59 +0.10 (+0.49%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wellington Management Group LLP Invests $1.19 Million in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Wellington Management Group LLP purchased a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 47,717 shares of the company's stock, valued at approximatelyDecember 20 at 3:39 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 44,229 shares of the company's stoDecember 19 at 3:15 AM | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Purchased by Jane Street Group LLCJane Street Group LLC raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 1,064.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 345,092 shares of the company's stock after acquiring an additional 315,456 shDecember 14, 2024 | marketbeat.comVerition Fund Management LLC Purchases New Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Verition Fund Management LLC purchased a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 26,784 shares of the company's stock, valued at approximately $66December 11, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Acquired by Fmr LLCFmr LLC lifted its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 36,925.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 696,810 shares of the company's stock after acqDecember 11, 2024 | marketbeat.com167,200 Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Acquired by Castleark Management LLCCastleark Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 167,200 shares of the company's stock, valued atDecember 8, 2024 | marketbeat.comInsider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 1,123 Shares of StockDecember 6, 2024 | insidertrades.comCerity Partners LLC Invests $834,000 in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Cerity Partners LLC purchased a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,384 shares of thDecember 6, 2024 | marketbeat.comParkman Healthcare Partners LLC Has $18.87 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Parkman Healthcare Partners LLC increased its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 16.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 755,244 shares of the company's stock after acquiring aDecember 4, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stock Holdings Increased by BNP Paribas Financial MarketsBNP Paribas Financial Markets raised its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 121.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 192,926 shares of the company's stock after buying anDecember 4, 2024 | marketbeat.comArrowMark Colorado Holdings LLC Has $13.28 Million Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)ArrowMark Colorado Holdings LLC lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 12.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 531,286 shares of the company's stock after selling 77,582 shares during theDecember 3, 2024 | marketbeat.comPDT Partners LLC Takes Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)PDT Partners LLC purchased a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 37,242 shares of the company's stock, valued at approxiDecember 2, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Purchased by Braidwell LPBraidwell LP raised its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 40.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,894,513 shares of the company's stock after buying an additNovember 29, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Rating of "Buy" from AnalystsKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has earned a consensus rating of "Buy" from the five brokerages that are presently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objNovember 27, 2024 | marketbeat.comAlgert Global LLC Increases Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Algert Global LLC lifted its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 390.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,159 shares of the companyNovember 27, 2024 | marketbeat.comKiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | globenewswire.comSegall Bryant & Hamill LLC Makes New $675,000 Investment in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Segall Bryant & Hamill LLC bought a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 27,026 shares of the company's stockNovember 25, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys 92,985 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Connor Clark & Lunn Investment Management Ltd. boosted its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 40.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 324,064 shares of the company's stockNovember 23, 2024 | marketbeat.comIs Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?November 13, 2024 | msn.comKiniksa Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNovember 12, 2024 | globenewswire.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $40.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. lifted their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Tuesday.November 5, 2024 | marketbeat.comHarbor Capital Advisors Inc. Acquires New Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Harbor Capital Advisors Inc. purchased a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 97,543 shares of the company's stock, valued at approximNovember 5, 2024 | marketbeat.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Consensus Rating of "Buy" by BrokeragesShares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price tNovember 2, 2024 | marketbeat.comKiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest ForecastsNovember 1, 2024 | finance.yahoo.comRice Hall James & Associates LLC Increases Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Rice Hall James & Associates LLC raised its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 8.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 649,630 shares of the company's stock aftNovember 1, 2024 | marketbeat.comKiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | seekingalpha.comBullish Outlook on Kiniksa Pharmaceuticals Driven by Arcalyst’s Billion-Dollar Potential and Strategic Growth InitiativesNovember 1, 2024 | markets.businessinsider.comKiniksa Pharmaceuticals Faces Financial Risks from Global Currency FluctuationsNovember 1, 2024 | markets.businessinsider.comWedbush Has Pessimistic Outlook of KNSA FY2024 EarningsKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Analysts at Wedbush decreased their FY2024 earnings per share estimates for Kiniksa Pharmaceuticals in a research report issued on Tuesday, October 29th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.42) perOctober 31, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $35.00Evercore ISI increased their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a research report on Wednesday.October 30, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Quarterly Earnings ResultsKiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The business had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. Kiniksa Pharmaceuticals's revenue for the quarter was up 67.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.20) EPS.October 30, 2024 | marketbeat.comAMI Asset Management Corp Purchases Shares of 51,262 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)AMI Asset Management Corp purchased a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 51,262 shares of the company's stock, valueOctober 30, 2024 | marketbeat.comQ3 2024 Kiniksa Pharmaceuticals Ltd Earnings CallOctober 30, 2024 | uk.finance.yahoo.comKiniksa sees FY24 ARCALYST revenue between $410M-$420MOctober 30, 2024 | markets.businessinsider.comWhat To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 EarningsOctober 29, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio ExecutionOctober 29, 2024 | finanznachrichten.deKiniksa Pharm's Revenue Surges 67% in Q3October 29, 2024 | fool.comKiniksa Pharmaceuticals trading halted, volatility trading pauseOctober 29, 2024 | markets.businessinsider.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Gap Down - Should You Sell?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shares Gap Down - Here's What HappenedOctober 29, 2024 | marketbeat.comKiniksa Pharmaceuticals International, plc 2024 Q3 - Results - Earnings Call PresentationOctober 29, 2024 | seekingalpha.comKiniksa partners with Carly Pearce in expansion of Life DisRPted campaignOctober 29, 2024 | markets.businessinsider.comKiniksa Pharmaceuticals Q3 2024 Earnings PreviewOctober 29, 2024 | msn.comExploring Kiniksa Pharmaceuticals's Earnings ExpectationsOctober 29, 2024 | benzinga.comHere's What Could Help Kiniksa Pharmaceuticals (KNSA) Maintain Its Recent Price StrengthOctober 29, 2024 | msn.comKiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio ExecutionOctober 29, 2024 | globenewswire.comSemanteon Capital Management LP Buys Shares of 22,057 Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)Semanteon Capital Management LP purchased a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 22,057 shares of the company's stock, valued at approOctober 29, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 12-Month High - Time to Buy?Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 12-Month High - Still a Buy?October 28, 2024 | marketbeat.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock, Option ChainOctober 27, 2024 | benzinga.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Stock Quotes, Forecast and News SummaryOctober 27, 2024 | benzinga.comKiniksa Pharmaceuticals (KNSA) Scheduled to Post Quarterly Earnings on TuesdayKiniksa Pharmaceuticals (NASDAQ:KNSA) will be releasing earnings before the market opens on Tuesday, October 29, Zacks reports.October 23, 2024 | marketbeat.com Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Cackling Kamala hates this company (Ad)Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. KNSA Media Mentions By Week KNSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNSA News Sentiment▼1.460.60▲Average Medical News Sentiment KNSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNSA Articles This Week▼23▲KNSA Articles Average Week Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cytokinetics News TG Therapeutics News Viking Therapeutics News BridgeBio Pharma News Crinetics Pharmaceuticals News Krystal Biotech News Arcellx News ADMA Biologics News Ultragenyx Pharmaceutical News Biohaven News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNSA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
